ArticleCell reports2016
Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- The application of nanoparticle-mediated siRNA delivery systems in ovarian cancer.Cancer gene therapy · 2026Review
- Article
- Myokines in cancer: bridging molecular mechanisms to biomarker discovery and therapeutic innovation.Frontiers in oncology · 2026Review
- Magnetic hyperthermia as an intracellular immunomodulatory technology: From heat transduction to tumor immune reprogramming.Theranostics · 2026Review
- Cholesterol depletion suppresses thermal necrosis resistance by alleviating an increase in membrane fluidity.Scientific reports · 2025Article
- Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Zwitterionic nanoparticles for thermally activated drug delivery in hyperthermia cancer treatment.Nanoscale · 2024Article
- ThermomiR-377-3p-induced suppression of Cirbp expression is required for effective elimination of cancer cells and cancer stem-like cells by hyperthermia.Journal of experimental & clinical cancer research : CR · 2024Article
- Ensemble learning model for identifying the hallmark genes of NFκB/TNF signaling pathway in cancers.Journal of translational medicine · 2023Article
- Development of handheld induction heaters for magnetic fluid hyperthermia applications andBiomedical physics & engineering express · 2023Article
- The Role of Hyperthermia in the Treatment of Peritoneal Surface Malignancies.Current oncology reports · 2022Review
- Hyperthermia enhances the efficacy of chemotherapeutic drugs in heat-sensitive cells through interfering with DNA damage repair.Annals of translational medicine · 2022Article
- Investigation of energy metabolic dynamism in hyperthermia-resistant ovarian and uterine cancer cells under heat stress.Scientific reports · 2021Article
- In vitro Ultrasonic Potentiation of 2-Phenylethynesulfonamide/Magnetic Fluid Hyperthermia Combination Treatments for Ovarian Cancer.International journal of nanomedicine · 2020Article
- Down-regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor.Journal of cellular and molecular medicine · 2019Article
- Overexpression of connective tissue growth factor is associated with tumor progression and unfavorable prognosis in endometrial cancer.Cancer biomarkers : section A of Disease markers · 2019Article
- Connective tissue growth factor mediates TGF-β1-induced low-grade serous ovarian tumor cell apoptosis.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 4 institutions in 4 countries.
Hiroto HatakeyamaDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Sherry Y WuDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Yasmin A LyonsDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Sunila PradeepDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Wanqin WangDepartment of Cancer Systems Imaging, MDACC, Houston, TX 77030, USA.
Qian HuangDepartment of Cancer Systems Imaging, MDACC, Houston, TX 77030, USA.
Karem A CourtDepartment of Chemical Engineering, University of Puerto Rico-Mayaguez, Mayaguez, PR 00681, Puerto Rico.
Tao LiuBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Song NieBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Cristian Rodriguez-AguayoDepartment of Experimental Therapeutics, MDACC, Houston, TX 77030, USA.
Fangrong ShenDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Yan HuangDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Takeshi HisamatsuDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Takashi MitamuraDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA; Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo 060-8648, Japan.
Nicholas JenningsDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Jeajun ShimDepartment of Systems Biology, MDACC, Houston, TX 77030, USA.
Piotr L DorniakDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA.
Lingegowda S MangalaDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNAs, MDACC, Houston, TX 77030, USA.
Marco PetrilloDepartment of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome 00168, Italy.
Vladislav A PetyukBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Athena A SchepmoesBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Anil K ShuklaBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Madeline Torres-LugoDepartment of Chemical Engineering, University of Puerto Rico-Mayaguez, Mayaguez, PR 00681, Puerto Rico.
Ju-Seog LeeDepartment of Systems Biology, MDACC, Houston, TX 77030, USA.
Karin D RodlandBiological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA.
Anna FagottiDepartment of Medicine and Surgery, Catholic University of the Sacred Heart, Rome 00168, Italy.
Gabriel Lopez-BeresteinDepartment of Experimental Therapeutics, MDACC, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNAs, MDACC, Houston, TX 77030, USA; Department of Cancer Biology, MDACC, Houston, TX 77030, USA.
Chun LiDepartment of Cancer Systems Imaging, MDACC, Houston, TX 77030, USA.
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center (MDACC), Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNAs, MDACC, Houston, TX 77030, USA; Department of Cancer Biology, MDACC, Houston, TX 77030, USA. Electronic address: asood@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USPacific Northwest National Laboratory · USUniversità Cattolica del Sacro Cuore · ITUniversity of Puerto Rico-Mayaguez · PR
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCERP50CA083639 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C · 1999 to 2015
$33.0MTargeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0MUPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Larkin Strong · 2002 to 2026
$23.8MPNNL Clinical Proteome Characterization CenterU24CA160019 · NCI · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI RODLAND, KARIN D, SMITH, RICHARD D · 2011 to 2016
$15.7MTexas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4MNovel extra cellular RNA-based combinatorial RNA inhibition therapyUH3TR000943 · NCATS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CALIN, GEORGE A., LOPEZ-BERESTEIN, GABRIEL · 2015 to 2017
$3.2MNCATS NIH HHS UH3 TR000943NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA083639NCI NIH HHS P50 CA098258NCI NIH HHS U24 CA160019NCI NIH HHS U54 CA096300NCI NIH HHS U54 CA151668
Abstract
Even though hyperthermia is a promising treatment for cancer, the relationship between specific temperatures and clinical benefits and predictors of sensitivity of cancer to hyperthermia is poorly understood. Ovarian and uterine tumors have diverse hyperthermia sensitivities. Integrative analyses of the specific gene signatures and the differences in response to hyperthermia between hyperthermia-sensitive and -resistant cancer cells identified CTGF as a key regulator of sensitivity. CTGF silencing sensitized resistant cells to hyperthermia. CTGF small interfering RNA (siRNA) treatment also sensitized resistant cancers to localized hyperthermia induced by copper sulfide nanoparticles and near-infrared laser in orthotopic ovarian cancer models. CTGF silencing aggravated energy stress induced by hyperthermia and enhanced apoptosis of hyperthermia-resistant cancers.
Indexed as
Hyperthermia, InducedAnimalsCell Line, TumorConnective Tissue Growth FactorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene SilencingGenes, NeoplasmHumansMiceModels, BiologicalOvarian NeoplasmsProteomicsUterine NeoplasmsCCN2 protein, humanConnective Tissue Growth Factorcopper sulfide nanoparticleCTGFDOPC-liposomehyperthermiaovarian cancerthermosensitivity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.